Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

LAVAL, QC / ACCESS Newswire / March 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver bett ...